Nasdaq · Common Stock · Pharmaceutical Preparations
18 entities across 7 jurisdictions, 3 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Jazz Pharmaceuticals Ireland Limited | Ireland | |
| Jazz Financing I DAC | Ireland | |
| Jazz Pharmaceuticals Operations UK Limited | United Kingdom | |
| Jazz Pharmaceuticals, Inc. | Delaware | |
| Jazz Pharmaceuticals Therapeutics, Inc. | Delaware | |
| Jazz Pharmaceuticals Research UK Limited | United Kingdom | |
| Gentium S.r.l. | Italy | |
| Jazz Pharmaceuticals UK Holdings Limited | United Kingdom | |
| Jazz Securities DAC | Ireland | |
| Jazz Financing Holdings Limited | Ireland | |
| Jazz Financing Lux S.à.r.l | Luxembourg | offshore centre |
| Jazz Pharmaceuticals International Limited | Ireland | |
| Jazz Investments Europe Limited | Malta | offshore centre |
| Jazz Capital Limited | Ireland | |
| Jazz Pharmaceuticals UK Limited | United Kingdom | |
| GW Pharmaceuticals Limited | United Kingdom | |
| Chimerix, Inc. | Delaware | |
| Jazz Investments I Limited | Bermuda | offshore centre |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $2.4B | $238.6M | $884.6M | — | 56,517,000 |
| FY2021 | $3.1B | −$329.7M | $750.9M | — | 59,694,000 |
| FY2022 | $3.7B | −$224.1M | $1.2B | — | 62,539,000 |
| FY2023 | $3.8B | $414.8M | $1.1B | — | 72,066,000 |
| FY2024 | $4.1B | $560.1M | $1.4B | — | 66,007,000 |
| FY2025 | $4.3B | −$356.1M | $1.3B | — | 60,981,000 |
15 institutions tracked — 8 added, 6 reduced, 1 opened a new position.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| FMR LLC | Active fund | 4,609,326 | +2,333,564 | $1.1B |
| BlackRock, Inc. | Index | 5,968,603 | +376,903 | $1.4B |
| Point72 Asset Management, L.P. | Hedge fund | 8,100 | −356,334 | $2.0M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 179,141 | −278,873 | $43.2M |
| CITADEL ADVISORS LLC | Hedge fund | 1,085,676 | −258,268 | $261.6M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 562,073 | −257,301 | $135.4M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 1,483,031 | +245,414 | $357.4M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,522,568 | +184,110 | $359.9M |
| BANK OF AMERICA CORP /DE/ | Active fund | 1,136,091 | +121,291 | $273.8M |
| STATE STREET CORP | Index | 1,999,816 | +108,170 | $481.9M |
| MORGAN STANLEY | Active fund | 629,680 | −69,058 | $151.7M |
| JPMORGAN CHASE & CO | Active fund | 1,160,786 | −43,567 | $276.6M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 98,390 | +42,462 | $23.7M |
| Capital World Investors | Active fund | 2,697,610 | +24,234 | $650.0M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Jazz Pharmaceuticals plc files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
